Proteome analysis has rapidly developed in the post-genome era and is now widely accepted as the complementary technology for genetic profiling. It has been shown to be a powerful tool for studying human diseases and for identifying novel prognostic, diagnostic and therapeutic markers. This review focuses on the identification of new biomarkers and therapeutic targets for renal cell carcinoma using different 'ome'-based technologies.
INTRODUCTION
Cancer represents one of the major life threatening diseases in humans that has stimulated interest in obtaining detailed insights into its molecular complexity. Several experimental strategies have been implemented for the molecular analysis of cancer, including genome scanning procedures such as comparative genomic hybridisation (CGH) techniques, DNA microarrays, restriction landmark genomic scanning (RLGS), cDNA and oligonucleotide arrays and serial analysis of gene expression (SAGE). These techniques allow large-scale analyses of gains and losses in chromosomal regions, alterations in the DNA methylation pattern and provide information on regulatory processes manifested as alterations in the mRNA, either resulting from changes in the rate of gene transcription or from mRNA degradation; however, they also have several inherent limitations, since posttranslational modifications (PTMs) and protein trafficking cannot be detected. Proteomic approaches allow the analysis of the abundance and the biochemical state of proteins to be carried out in a comprehensive manner. Proteome-based profiling of cancer has the potential to identify a novel set of proteins which is differentially expressed in tumours in comparison with autologous normal tissue. This is expected to lead to the characterisation of diagnostic, prognostic and therapeutic markers as well as to novel classifications of diseases and tumour subtypes. This information can then be utilised for the development of individually tailored therapies based on the existence of disease-related proteins in patients with tumours.
Using 'ome'-based technologies, a number of putative prognostic and therapeutic markers have been identified in renal cell carcinoma (RCC). Some of these antigens appear to be tumour specific or differentially expressed, suggesting their use as biomarkers and/or targets for novel immunotherapies.
RENAL CELL CARCINOMA
RCC is one of the ten most frequent malignancies in Western societies, with an increased incidence over the past 20 years. It represents approximately 3 per cent of all diagnosed malignancies and accounts for up to 95,000 deaths per year worldwide. 1 It is a phenotypically and genetically heterogeneous disease, which is classified based on morphological and genetic differences. This classification distinguishes metanephric adenoma, oncocytoma and papillary adenoma as benign tumours from the clear cell, papillary/chromophilic, chromophobic and collecting duct RCC. Most sporadic tumours, which are rare in patients younger than 40 years, belong to the clear cell RCC subtype, originating from the proximal tubule. The papillary/ chromophilic RCC -representing the most common form of the non-clear cell RCC -is also derived from the proximal tubule. This classification also has clinical relevance, since the prognosis of patients with chromophobic RCC originating from the distal tubule is significantly better than that with clear cell and papillary/chromophilic RCC.
Initiation and progression of RCC is associated with an accumulation of genetic changes involving numerous different genes. Molecular studies examining the frequency and biological significance of genetic alterations have demonstrated a high degree of genetic heterogeneity in RCC. 2, 3 Cytogenetic studies have implicated a number of chromosomal loci as important for the development of this disease. Clear cell RCC is characterised by complex chromosomal alterations. The most common DNA losses in this RCC subtype involve chromosomes 3p, 4q, 6q, 9p, 13q, 14q and Xq, whereas DNA gains often involve chromosomes 5q, 7 and 17. The loss of the short arm of chromosome 3p is clearly linked to the development of clear cell RCC and occurs in 40 to 70 per cent of tumours of this histological subtype. 4 Renal tumours of predominantly papillary/chromophilic architecture are characterised by trisomies and tetrasomies of chromosomes such as 3q, 7, 8p, 12q, 16q 17 and 20q, and losses on chromosomes 1p, 4q, 6q, 9p, 13q and Y. For example, mutations in the von Hippel-Lindau disease tumour suppressor gene located in the chromosomal region 3p21 appear to be involved in the development of clear cell RCC, but this gene acts in concert with additional genes. 5 The gain of chromosome 7, which is particularly linked to the encoded locus of the epidermal growth factor receptor, may confer growth advantage to some malignant cells. 6 Chromophobic RCC exhibits the loss of many chromosomes (1, 2, 3, 6, 10, 13q, 17 and 21) , which is a relatively unique feature in solid tumours. 3, 7 In addition, chromophobic RCC shows both quantitative and qualitative changes in mitochondrial DNA. 8, 9 At presentation, fewer than 40 per cent of RCC patients have a tumour confined to the kidney. The rate of detection for confined tumours is reported to have increased over the last ten years but, at the time of diagnosis, most patients are asymptomatic for RCC and tumours are discovered by chance during investigations for unrelated conditions, meaning that many already have metastatic cancer. 10 To date, tumour stage and grade are the most useful clinical prognostic indicators for patients with RCC. The overall five-year survival for RCC patients is 62 per cent, ranging from 16 to 32 per cent for those with metastatic disease.
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The main treatment for localised disease is surgical resection, whereas the efficacy of other treatment modalities, such as chemotherapy and radiotherapy, is rather limited. Based on high levels of T cell infiltration, the isolation and/or generation of a number of CD8 þ cytotoxic T lymphocytes (CTLs) with the capacity to lyse both autologous and allogeneic RCC cell lines, the high frequency of spontaneous regressions and the response rates to cytokine-based therapies such as interleukin (IL)-2 and interferon (IFN)-AE, RCC appears to be an immunogenic tumour. Treatment of this disease with cytokines is proving promising, but is still limited, with objective response rates of lower than 20 per cent. 12 Thus, the development of anti-cancer vaccines has rekindled interest in the treatment of RCC, with the aim of activating immune defence mechanisms against the tumour. 13 Vaccination with dendritic cells fused with autologous tumours appears to have potential clinical RCC is a chemotherapyand radiotherapyresistant tumour RCC subtype-specific chromosomal alterations were frequently found RCC is considered to be an immunogenic tumour A number of RCCassociated antigens have been defined via cellular, humoral or in situ immunity benefits with little toxicity, 14 whereas vaccination with immature dendritic cells pulsed with autologous tumour antigens in combination with IL-2 had little benefit for patients with advanced RCC. 15 Allogeneic peripheral blood stem cell transplantation of RCC patients appears to induce a graft versus tumour response. 16 Other immunotherapies, such as peptide, DNA and RNA vaccination, have been further facilitated by the identification of tumour-associated antigens (TAAs). Even though RCC vaccines appear to be very promising tools, such approaches are currently limited, as only a few RCC-specific antigens have been defined. Thus, there is an urgent need for the identification of novel tumour-specific antigens.
RCC-SPECIFIC BIOMARKERS IDENTIFIED BY IMMUNE RESPONSE-BASED APPROACHES
Although tumour lesions show substantial lymphocytic infiltrates, these tumour infiltrating lymphocytes (TILs) often lack in vivo cytolytic activity, which might be linked to the tumour micro-milieu. This might explain the limited number of RCC-reactive TILs generated so far; however, the isolation of tumour-specific CTLs or TILs which recognise and eliminate autologous and allogeneic RCC cell lines represents a prerequisite for the characterisation of a number of RCCrelated tumour antigens. The target antigens were identified by screening COS cells transfected with a combination of the respective HLA restriction elements, along with cDNA libraries derived from mRNA isolates of the tumour cells/tissue using tumour-reactive CTLs. Many of these antigens have been restricted to a small number of tumours. They include RAGE1, [17] [18] [19] RU2AS, 20 a non-AUG-defined alternative open reading frame of the intestinal carboxyl esterase (ICE), 21 fibroblast growth factor (FGF)-5 22 and mutated forms of HLA-A2, 23 heat shock protein (hsp)70 24 and cytochrome B, respectively 25 ( Table 1) . In this context, it is noteworthy that cancer-testis (C/T) antigens, which are expressed in normal tissues almost exclusively in germ-line cells, are frequently found in a variety of tumour types, but are rarely detectable in RCC. 26 The expression of some prominent C/T antigens can be induced by 2'5'-desoxyazacytidine treatment, however, suggesting that lack of C/T antigen expression in RCC is attributable to their methylation status. 27 The RAGE1 antigen represents the first antigen identified by an autologous cytotoxic T cell clone on a renal tumour. It is expressed at a high frequency in Analogous to hsp70-2, the mutated HLA-A2 antigen represents a highly specific TAA for the given tumour cells, but clearly has no broad application. Another RCC-specific point mutation that frequently occurs in RCC is delineated from cytochrome B. The mutated protein is expressed in approximately 50 per cent of the RCC lines examined. These cytochrome B variant-expressing RCC cell lines were susceptible to lysis by a Vª3/Vä1 þ T cell clone, which was originally isolated from an RCC TIL population. Normal kidney cells, melanoma, fibroblasts and Burkitt's lymphoma did not express this antigen, as demonstrated by immunohistochemistry using a cytochrome B-specific monoclonal antibody (mAb), whereas some breast cancer lines showed a positive staining pattern.
FGF-5 is a tumour antigen which is over-expressed not only in the majority of RCCs, but also in prostate and breast carcinomas; however, its marginal expression level in normal tissues -which is below the recognition threshold of the defining CTL clone -might still trigger autoreactivity by more sensitive CTLs.
Besides the classical approach using cDNA expression cloning, mass spectrometry-assisted sequencing of peptides eluted from tumour cells 28 and 'reverse immunology', which employs the prediction of MHC class I ligands from a selected TAA in silico followed by their verification as T cell epitopes, have been undertaken. [29] [30] [31] [32] The major drawbacks of T cell-based technologies used for the identification of TAAs are the timeconsuming cell cultures and, as experienced in most cases, the low frequency of pre-existing tumour-specific T cells represented in peripheral blood samples.
The development of the serological analysis of cDNA expression libraries (SEREX) by Sahin et al. for the identification of tumour-specific antigens serologically recognised by the patient's immune system is a T cell-independent approach. 33 So far, more than 1,500 antigens have been identified using this method, but only a small number of antigens have been sequenced, of which approximately 30 per cent are novel antigens. With this technology, 84 potential RCC antigens have been identified, including carbonic anhydrate (CA) XII, gene 21, the kinases LK B1/ STK11 and bcr, as well as the potential tumour suppressor SNC6 (Table 1) . 34, 35 The majority of these antigens have not been tested as suitable models to evaluate their potential as immunogens. Thus, the immune response-based methods for tumour antigen identification are technically demanding, expensive, time consuming and often not feasible for monitoring a large series of tumours. It is noteworthy, however, that RCCexpressed TAAs have been described in other tumour entities. These include members of the MAGE family, 36 PRAME, 26, 31 HER-2/neu, 37 SART3 38 and MUC1 (Table 1) . 39 In addition, some TAAs are not constitutively expressed in RCC but are induced upon treatment with the demethylating agent 2'5'desoxy-azacytidine. 27 Furthermore, the membrane antigen (MN)/CA IX has been identified as a tumour marker on the basis of reactivity of the G250 mAb, 40 which was raised against an RCC cell line and was Features and limitations of antigens defined by immune response-based strategies detectable in the majority of samples from clear cell RCC (Table 1) .
IDENTIFICATION OF NOVEL RCC-ASSOCIATED GENES BY TRANSCRIPTOME-BASED TECHNOLOGIES
Several technologies are currently available for the analysis of the genomewide patterns of mRNA expression. Microarray technology is a method that has been widely utilised for the analysis of mRNA expression patterns of tumours and corresponding normal tissues. Two experimental strategies for the performance of such analyses exist. The first approach relies on the robotic printing of defined target cDNAs onto glass slides, which are subsequently hybridised to two differentially labelled fluorescent radiolabelled probes representing mRNAs/cDNAs of diverse cell origins (eg tumour versus normal tissue). The second is based on the synthesis and coupling of a large number of oligonucleotides to chips supplied by Affymetrix, using cDNA poolsgenerated from mRNA isolated from cells and/or tissues -as fluorescent/ radiolabelled probes. The resulting signal intensities of the distinct labelled probes are subsequently monitored and the ratio information obtained following image processing.
These different microarray technologies provide important tools for the global characterisation of tissues and/or cell lines and have been utilised for the molecular classification of a number of cancer types, including melanomas, breast carcinomas, B cell lymphomas, colon carcinomas, adrenocortical tumours, glioblastomas and neuroblastomas. [41] [42] [43] Recently, systematic searches for novel tumour antigens of RCC on the basis of their tumour-specific transcriptional profiles have also been performed. Transcriptomes of tumours and normal tissues were assessed by either representational difference analysis (RDA) 44, 45 or by microarray technology. 32, [46] [47] [48] [49] More than 1,700 differentially expressed genes/cDNAs have been detected. The data obtained from such analyses were at least partially evaluated by either real-time polymerase chain reaction and/or immunostaining. Using both approaches, gene expression alterations were identified which were (i) common to RCCs; (ii) distinctive for specific RCC subtypes, eg clear cell versus chromophobic; and (iii) unique to specific clinical subsets of this disease, such as pretreated versus untreated patients ( Table  2 ). The functional annotation of these genes provided views of changes in the activities of specific biological pathways in RCC compared with normal kidney epithelium. These include: oncogenes; tumour suppressor genes; genes involved in angiogenesis, antigen processing, cell adhesion/motility, signal transduction and nucleotide metabolism; and genes which have already been described as overexpressed in other cancers, including cyclin D, CA IX, parathyroid hormonelike hormone and adipophilin. 32, [46] [47] [48] [49] Furthermore, 9D7 was identified as a novel gene over-expressed in RCC as well as in other cancers. 45 Besides the differential expression pattern of tumour versus normal cells, there exists a significant distinction in the gene expression profile of tumours obtained from patients with a relatively nonaggressive, compared with a relatively aggressive, form of disease, 47 and of tumours with distinct subtypes. Thus, transcription profiling is a powerful tool for monitoring patients' tumours; this may also have an impact on cancer diagnosis and prognosis and, consequently, on the mode of therapy selected.
DIFFERENT PROTEOME-BASED TECHNOLOGIES EMPLOYED FOR THE IDENTIFICATION OF BIOMARKERS IN RCC
The use of transcriptomics, as well as cDNA differential display, precludes the Transcriptome-based analyses allow the identification of differentially expressed genes in RCC Table 2 : Antigens identified by transcriptome-based analysis [50] [51] [52] [53] The standard approach for proteomics is the comparison of two types/ states of samples (eg tumour versus normal renal epithelium/treated versus untreated) maintained and generated under fairly identical conditions, mainly utilising the separation of proteins by two-dimensional gel electrophoresis (2DE). Limitations of this approach are the complexity of the method, the limited dynamic range of the common staining procedures covering three to five orders of magnitude, compared with nine assumed within a eukaryotic cell, and difficulties in adequate separation of hydrophobic, very large or very small proteins, as well as proteins displaying extreme pIs and membrane proteins. 2DE is followed by the identification of gel-separated proteins by mass spectrometry in combination with computer-assisted tools. The latter allows the construction of protein databases and the retrieval of qualitative and quantitative information regarding experimental design, samples, gels, spots and matches (Figure 1) . 54, 55 In addition, there exist alternatives to 2DE gels, which include liquid-based protein/peptide separations 56 and protein chips, either to assay protein abundance in a similar way to microarrays for assessing RNA abundance or to identify protein targets of specific probes (Table 3) . Furthermore, proteome studies of cells via surface-enhanced laser desorption ionisation (SELDI) spectrometry analysis can be employed for reproducible protein profiling directly from crude samples ( Table 3 ). This method was also successfully implemented for the identification of protein fingerprints in RCC, which might serve as potential 
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diagnostic or prognostic markers. 57 Thus, the application of proteomics not only allows the simultaneous expression profiling of multiple genes in tissues and/or cell lines, but also the identification of also protein modifications which might be linked or restricted to specific tumour types, and which frequently occur in cancers. These include, for example, phosphorylation, glycosylation, carboxylation, acetylation, alkylation and sulphation.
>There are various different strategies for monitoring the protein expression pattern of tumours: (i) the solely comparative analysis of unfractionated or microdissected lysates of tumours and normal tissues (classical proteomics); (ii) the comparative analysis of secreted proteins, membrane fractions and subcellular compartments of different tumour cell lines to identify potential markers that are restricted to specific tumour types (analysis of sub-proteomes); and (iii) the identification of tumour proteins that induce antibody responses. This experimental approach is termed either PROTEOMEX, 58, 59 SERPA (serological proteome analysis) 60 or SPEARS (serological and proteomic evaluation of antibody responses; Figure  1 ). 61 It is based on the separation of proteins from tumours and autologous normal tissue by 2DE, followed by Western blot analysis using either patient or control sera. Subsequently, immunoreactive proteins differentially recognised by sera samples are analysed by mass spectrometry. Such protein antigens and/or their corresponding antibodies could be assayed for diagnostic and prognostic measures in serum or other biological fluids of patients. Recently, such proteome-based approaches have been successfully used in a large series of tumour types, including neuroblastoma, lung cancer and breast carcinoma, as well as RCC.
LIMITATIONS OF PROTEOME-BASED TECHNOLOGIES FOR THE CHARACTERISATION OF RCC MARKERS
Currently, the number of reports applying proteome-based approaches to the investigation of either RCC cell lines or surgically removed lesions is still limited. This might be due to difficulties in obtaining enough tumour material and purified normal epithelial cells, from the heterogeneous histological specimen.
One crucial step is the separation and partial purification of epithelial cells to obtain reproducible patterns for the analysis of differences between normal and tumour tissues. Furthermore, the collection of the relevant cell population of sufficient quantity and quality is a substantial challenge. Cell lines and primary cell cultures can circumvent these problems, but may also produce in vitro artefacts due to the applied culture Limited by binding capacity. Rather suited for the analysis of body fluids than of whole cellular extracts. Strong binders to matrixes might displace weak binders.
PROTEOMEX Direct assessment of immunoreactive target structures; highly sensitive read-out system; suited for high-throughput analyses; independent of artefacts associated with sample preparation; most valuable in combination with proteomics data.
Requires access to clinical samples (biopsy material, sera) and patient data.
conditions. Thus, so far the heterogeneity of RCC tumour material cannot be excluded, although some work has been carried out employing laser capture microdissected RCC material, which circumvents the contamination problem. 61, 62, 63 It is noteworthy, however, that RCC samples from areas in which there was no macroscopic evidence of necrosis or fibrosis are of relative purity and may account for the lack of enrichment in the dissected samples. 62 To further improve proteome analysis for RCC protein characterisation, subproteomes will have to be analysed. These might be based on: (i) the employment of narrow pH gradients for 2DE, which allows low abundance proteins to be mapped and separation of overlapping protein spots within broad range gels; (ii) the investigation of specific cellular compartments; or (iii) sequential sample extractions. 64 For example, Starita-Geribaldi and coworkers isolated basolateral membrane from RCC cells and subjected it to conventional proteome analysis. 65 This led to the identification of the protease SP220 as a potential RCC marker.
Although subproteome analyses led to an enormous reduction in sample complexity, and thus allowed the retrieval of a maximum amount of information within the given subproteome, the concept is limited by the availability of sufficient material and hence is more applicable for the analysis of established RCC and normal renal epithelium cell lines than for analyses of tumour lesions. Despite their resolution power, these analyses are often hampered by the very limited biopsy material or by high sample throughput screening.
IDENTITY OF BIOMARKERS IN RCC DETECTED BY PROTEOME-BASED ANALYSIS
Most of the analyses employed conventional proteomics and only rarely PROTEOMEX to identify potential RCC-specific target structures. 2DE profiling of RCC cell lines and tissues, as well as respective controls obtained from normal kidney epithelium, revealed a number of proteins associated with RCC. 58, 59, 61, [66] [67] [68] [69] [70] [71] These belong to different protein families, including heat shock proteins (HSPs), antigen processing components, enzymes involved with cellular metabolism and cytoskeletal proteins ( Table 4) . Some of these markers exhibiting alternate expression in RCC when compared with normal kidney have also been demonstrated in other malignancies. The ubiquitinol cytochrome C reductase, NADHubiquinone oxidoreductase complex 1 and isoforms of the plasma glutathione peroxidase were expressed in normal kidney cells but not in RCC samples. Since these proteins are encoded on chromosomes for which loss of heterozygosity has frequently been detected in RCC, lack of expression might be caused by unknown structural alterations. By contrast, isoforms of manganese superoxide dismutase (Mn-SOD) were not present in normal kidney tissue, but were highly expressed in RCC. Some other antigens, such as transcriptional control tumour protein (TCTP), which is a growth-related protein with a housekeeping function, are ubiquitously expressed in healthy and normal cells, but not in RCC. 72 In addition, the authors' group described a large series of proteins which are differentially expressed in RCC cell lines or tumour lesions when compared with normal kidney epithelium (Table 4) . For example, the cytoskeletal protein vimentin is expressed at very low levels in normal kidney when compared with RCC samples. Interestingly, the expression pattern of vimentin and cytokeratin (CK) also varied significantly between the RCC subtypes. Moreover, monitoring of RCC with a combination of anti-vimentin and anti-CK 8-specific antibodies allows the distinction between RCC of the clear cell type to that of A series of differentially expressed proteins and immunoreactive target structures have been defined by proteomebased strategies chromophobic type. 71 Thus, proteomics can be successfully employed for the identification of diagnostic markers.
The approach of combining serology with proteomics technology, which is termed PROTEOMEX, SERPA or SPEARS, was also applied to RCC but there is only limited information on using this strategy: Klade et al. described two differentially expressed antigens in RCC. 60 The smooth muscle protein 22-AE (SM22-AE) is an actin-binding protein with unknown function. It is predominantly expressed in smooth muscle cells but has also been found in the tumour stroma of RCC, as well as in colon carcinomas. In addition, this group described CA-I. 60 In this context, it is noteworthy that over-expression and immunogenicity of another CA family member (CA-IX) has been shown in RCC. 73, 74 In addition, Unwin and coworkers identified a number of candidate immunogens with relatively high expression levels in tumour tissues compared with normal kidney epithelium. 61 These proteins include annexin 1 and 4, thymidine phosphorylase, CA-I, manganese superoxide dismutase (Mn-SOD) and the major vault protein. Interestingly, the guanine nucleotide-binding protein (GBB1) and the lactate dehydrogenase H (LDH-H) protein are significantly downregulated in RCC when compared with normal kidney cells. Furthermore, the authors' own group extended these studies and identified an additional series of antigens by the PROTEOMEX approach (Table 4) .
In this context, it is noteworthy that there are only a few studies describing PTMs of biomarkers in RCC. 75 Although proteomics is a valuable tool for their detection, so far merely isoforms of plasma glutathione peroxidase, Mn-SOD and hsp27 have been described in RCC by proteome-based technology. 67, 69 The low number of PTMs detected in RCC samples is currently limited by the scarce number of systems analysed; however, recent findings derived from further analyses of RCC, in particular of the clear cell subtype, seem to indicate that predominantly mitochondrial proteins involved in the regulation of the cellular redox state or in detoxification processes, as well as proteins associated with cellular 
SELECTED BIOMARKERS IN RCC IDENTIFIED BY PROTEOME-BASED TECHNOLOGY Heat shock proteins
HSPs are highly conserved and ubiquitously expressed. They are classified according to their molecular weight into four major families, which comprise several members and exhibit a distinct constitutive and inducible expression pattern. 76, 77 HSPs can be induced in cells upon exposure to environmental stress, including heat shock and oxidative stress, as well as due to pathophysiological conditions. Thus, HSPs exert multiple physiological functions, such as the regulation of cellular homeostasis and apoptosis, as well as pathophysiological functions, including an important role in tumour antigenicity and T cell-mediated anti-tumour reactivity. High expression levels of different members of the family have been described in human cancers and may serve as prognostic markers in some diseases. There is little information about the role of HSPs in RCC, although over-expression of hsp27 and hsp72 has been found and appeared to be of clinical relevance. 78 The identification of a point mutation in hsp70-2 of a primary RCC lesion argues for a role for HSPs in the immunogenicity of the disease. A heterogeneous expression pattern of various members of distinct HSP families has recently been described in RCC and corresponding normal kidney epithelium, using conventional proteome and PROTEOMEX analyses. 69 In particular, high levels of hsp27 expression were found in RCC when compared with normal kidney cells. Since HSP serum concentrations in tumour patients appear to be of prognostic value in some malignancies, PROTEOMEX analyses were performed. An individual spot pattern, in terms of the number of spots reacting with a given patient's serum, was obtained. All HSP family members defined by conventional proteomics were found to react with patients' and/or control serum; the respective spot pattern was reproducible between the different experiments. 69 Furthermore, different isoforms were detected by PROTEOMEX.
Cytoskeletal proteins
During malignant and viral transformation of epithelial cells, the cytoskeletal organisation is altered, depending on the nature of the transforming agent as well as the differentiation grade of tumours. Different components of the cytoskeleton play an important role in tumour vascularisation, the control of cell adhesion, the invasiveness and the metastatic potential of cancer cells. Intermediate filaments (IFs), which represent the major cytoskeletal components of mammalian cells, are dynamic structures in vivo. Members of the IF family include vimentin and cytokeratins, whose simultaneous expression is often associated with a dedifferentiation, enhanced invasion, migration and metastatic potential of tumours. 79, 80 Using proteomics and/or PROTEOMEX, a number of candidate antigens representing members of the cytoskeletal family, such as cytokeratins -particularly cytokeratin 8 -cytoskeletal tropomyosin, F-actin capping protein, ª-actin, SM22-AE, stathmin, tubulin-AE, tubulin-â and vimentin, were identified. 45 
Metabolic enzymes
Early proteome-based studies demonstrated a differential expression pattern of metabolic enzymes in normal kidney tissue and RCC lesions. Some of these enzymes such as Mn-SOD, 67 are over-expressed in RCC, whereas others, like aldehyde dehydrogenase-1, aminoacylase-1, enoyl-CoA hydratase, AEglycerol-3-phosphate dehydrogenase and plasma glutathione peroxidase demonstrated a diminished expression in RCC. 67, 81 . In addition, ubiquinone cytochrome-C reductase and the mitochondrial NADH-ubiquinone oxidoreductase complex I lack expression in RCC. 66 Thus, the tumour status of RCC appears often to be associated with alterations in metabolic enzymes. This theory has been further confirmed, and even extended, by recent reports targeting SOD, triosephosphate isomerase, thioredoxin, thymidine phosphorylase, CA-I and ubiquitin carboxyl-terminal hydrolase. 61, 70 This is in line with other reports and suggests that the tumour status of RCC is indeed associated with a number of alterations in the expression profile of metabolic pathways. For example, an abnormally high glycogen deposition in RCC cells is caused by changes in the intracellular flux of metabolites attributable to altered enzyme activities. Furthermore, a decreased expression of the glucose-6-phosphatase enzyme in carbohydrate metabolism has been demonstrated in RCC cells by comparison with normal kidney cells. 82 It can be speculated, however, that there are other potentially significant biochemical and/or molecular changes associated with RCC, which still remain to be identified.
CONCLUSIONS
Proteins are detectable in tumour tissues due to differences in their abundance or their antigenic properties. Classical proteomics, identifying differentially expressed proteins, and PROTEOMEX, detecting immunogenic proteins, are therefore complementary technologies; however, it is expected that identified components utilising both methods will partially overlap. PROTEOMEX helps to eliminate components resulting from a stress reaction of a cell or tissue because no fast cell responses are displayed. Furthermore, it has the potential to identify tumour-relevant proteins which are targets because of a change in their PTM or in their structure.
As expected, PROTEOMEX in RCC demonstrated a partial overlap with differentially expressed biomarkers (Table  4) . This overlap was especially noticeable for some metabolic enzymes, like enolase-1, glutathione S-transferase, HSPs, ubiquitin carboxy-terminal hydrolase, as well as for the cytoskeletal component vimentin. Comparison of transcriptomeand proteome-based technologies also detected an overlap of targets identified (Table 5, Table 6 ). Since transcriptomics is independent of the protein amounts and does not detect PTMs, it is not possible to completely unravel the biological process if only mRNA levels are analysed.
Despite the major advances in recent RCC studies using integrated functional genomics and proteomics (Figure 2) , the discovery of an early biomarker suited for the diagnosis or prognosis of RCC has still not occurred. This appears in part attributable to an enormous heterogeneity in this tumour entity. There should be a subdivision of the analysis, focusing on the different types of RCC as well as addressing tumour grading and staging. Various transcriptome and/or proteome approaches should now be undertaken to further expedite the process for this identification. A combination of expression analysis based on cDNA array or proteome technology in combination with epitope prediction will provide the basis for the selection of individual peptides which can be implemented for individually tailored immunotherapies. The integrated functional genomics approach has recently been successfully implemented for an optimised identification of TAA epitopes in RCC (Figures 2 and 3) . 32 An important advantage of the targeted PROTEOMEX technique of combining serology with proteomics, is its ability to provide a large amount of information in relatively few experiments. Furthermore, it excludes the possible effects induced by sample preparation followed by classical proteomics, which might lead to artefacts.
The knowledge obtained from such experiments, however, is only the first step in understanding the physiological and pathophysiological processes involved in kidney tumours. Hypothesis-driven experiments focusing on mechanisms of the regulatory processes of proteins identified by proteome-based studies will be necessary to provide more valuable information. 
